不可切除或转移性胃肠道间质瘤患者伊马替尼治疗前后血清胰岛素样生长因子-1水平及其临床意义

 目的　探讨不可切除或转移性胃肠道间质瘤（GIST）患者伊马替尼治疗前后血清胰岛素样生长因子-1（IGF-1）水平变化及其临床意义。方法　收集27例不可切除或转移性GIST患者伊马替尼治疗前（治疗前组）、伊马替尼治疗3个月后（治疗后组）及20名健康志愿者（健康对照组）血清标本。用酶联免疫吸附法检测各血清标本IGF-1水平。结果　不可切除或转移性GIST患者伊马替尼治疗前组血清IGF-1平均水平为（463.61±120.98）ng／ml，高于健康对照组的（115.75±39.27 ）ng／ml,差异有统计学意义（t＝12.355，P＝0.000）。伊马替尼治疗后组血清IGF-1平均水平为（244.64±100.11）ng／ml，较治疗前组的（463.61±120.98）ng／ml明显降低,差异有统计学意义（t＝7.582，P＝0.000）。结论　血清IGF-1水平可能有助于判断GIST的疗效、进展、复发或转移。

Serum IGF-1 levels and its clinical significance in patients with unresectable or metastatic gastrointestinal stromal tumors before and after imatinib treatment

Objectives To explore the serum insulin-like growth factor-1 （IGF-1） levels in the patients with unresectable or metastatic gastrointestinal stromal tumors before and after imatinib treatment and to discuss its clinical significance. Methods The serum samples of 27 patients with unreseetable or metastatic gastrointestinal stromal tumors were colleeted before imatinib treatment（before treatment group） and three months after imatinib treatment （after treatment group）.The other serum samples were collected from 20 healthy volunteers who were accepting health examination （control group）. The serum IGF-1 levels of＇the samples were determined by enzyme-linked immunosorbent assay （ELISA）. Results The mean serum IGF-1 levels were significantly higher in before treatment group than in control controls （463.61＋120.98） ng/ml vs. （115.75±39.27） ng/ml, t=-12.355, P=0.000）]. Three months after imatinib treatment ,the mean serum IGF-1 levels were significantly lower in after treatment group than in before treatment group （244.64±100.11）ng/ml vs. （463.61±120.98） ng/ml, t=7.582,P=0.000]. Conclusions Serum IGF-1 levels may help to judge therapeutic effect, progression, recurrence or metastasis of the gastrointestinal stromal tumor.